vs
EverCommerce Inc.（EVCM）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是EverCommerce Inc.的1.4倍（$207.3M vs $151.2M），EverCommerce Inc.净利率更高（4.0% vs -62.0%，领先66.0%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 5.2%），EverCommerce Inc.自由现金流更多（$21.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 4.7%）
EverCommerce Inc.是面向服务类中小企业的领先集成SaaS解决方案提供商，核心市场覆盖北美及部分全球区域，产品线包含业务管理、支付处理、客户互动、营销工具等，服务家庭服务、健康康养、健身等多个细分领域。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
EVCM vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $151.2M | $207.3M |
| 净利润 | $6.0M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 8.8% | -54.7% |
| 净利率 | 4.0% | -62.0% |
| 营收同比 | 5.2% | 25.9% |
| 净利润同比 | 149.4% | 3.5% |
| 每股收益（稀释后） | $0.04 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $151.2M | $207.3M | ||
| Q3 25 | $147.5M | $159.9M | ||
| Q2 25 | $148.0M | $166.5M | ||
| Q1 25 | $142.3M | $139.3M | ||
| Q4 24 | $143.7M | $164.6M | ||
| Q3 24 | $140.1M | $139.5M | ||
| Q2 24 | $140.5M | $147.0M | ||
| Q1 24 | $137.9M | $108.8M |
| Q4 25 | $6.0M | $-128.6M | ||
| Q3 25 | $11.1M | $-180.4M | ||
| Q2 25 | $8.2M | $-115.0M | ||
| Q1 25 | $-7.7M | $-151.1M | ||
| Q4 24 | $-12.2M | $-133.2M | ||
| Q3 24 | $-9.2M | $-133.5M | ||
| Q2 24 | $-3.4M | $-131.6M | ||
| Q1 24 | $-16.3M | $-170.7M |
| Q4 25 | 8.8% | -54.7% | ||
| Q3 25 | 10.8% | -106.9% | ||
| Q2 25 | 10.7% | -64.8% | ||
| Q1 25 | 10.0% | -102.6% | ||
| Q4 24 | 8.8% | -74.3% | ||
| Q3 24 | 7.2% | -94.6% | ||
| Q2 24 | 5.5% | -79.1% | ||
| Q1 24 | -3.1% | -151.9% |
| Q4 25 | 4.0% | -62.0% | ||
| Q3 25 | 7.5% | -112.8% | ||
| Q2 25 | 5.5% | -69.0% | ||
| Q1 25 | -5.4% | -108.5% | ||
| Q4 24 | -8.5% | -80.9% | ||
| Q3 24 | -6.5% | -95.7% | ||
| Q2 24 | -2.4% | -89.5% | ||
| Q1 24 | -11.8% | -156.8% |
| Q4 25 | $0.04 | $-1.28 | ||
| Q3 25 | $0.06 | $-1.81 | ||
| Q2 25 | $0.04 | $-1.17 | ||
| Q1 25 | $-0.04 | $-1.57 | ||
| Q4 24 | $-0.06 | $-1.34 | ||
| Q3 24 | $-0.05 | $-1.40 | ||
| Q2 24 | $-0.02 | $-1.52 | ||
| Q1 24 | $-0.09 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.7M | $421.0M |
| 总债务越低越好 | $523.4M | — |
| 股东权益账面价值 | $716.9M | $-80.0M |
| 总资产 | $1.4B | $1.5B |
| 负债/权益比越低杠杆越低 | 0.73× | — |
8季度趋势，按日历期对齐
| Q4 25 | $129.7M | $421.0M | ||
| Q3 25 | $106.9M | $202.5M | ||
| Q2 25 | $151.1M | $176.3M | ||
| Q1 25 | $148.4M | $127.1M | ||
| Q4 24 | $135.8M | $174.0M | ||
| Q3 24 | $101.6M | $150.6M | ||
| Q2 24 | $86.7M | $480.7M | ||
| Q1 24 | $90.0M | $112.3M |
| Q4 25 | $523.4M | — | ||
| Q3 25 | $524.6M | — | ||
| Q2 25 | $525.8M | — | ||
| Q1 25 | $526.9M | — | ||
| Q4 24 | $527.9M | — | ||
| Q3 24 | $529.0M | — | ||
| Q2 24 | $530.1M | — | ||
| Q1 24 | $531.1M | — |
| Q4 25 | $716.9M | $-80.0M | ||
| Q3 25 | $728.5M | $9.2M | ||
| Q2 25 | $744.0M | $151.3M | ||
| Q1 25 | $739.6M | $144.2M | ||
| Q4 24 | $750.8M | $255.0M | ||
| Q3 24 | $770.7M | $346.8M | ||
| Q2 24 | $784.1M | $432.4M | ||
| Q1 24 | $800.7M | $140.3M |
| Q4 25 | $1.4B | $1.5B | ||
| Q3 25 | $1.4B | $1.2B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.4B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.5B | $1.6B | ||
| Q1 24 | $1.5B | $1.3B |
| Q4 25 | 0.73× | — | ||
| Q3 25 | 0.72× | — | ||
| Q2 25 | 0.71× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 0.70× | — | ||
| Q3 24 | 0.69× | — | ||
| Q2 24 | 0.68× | — | ||
| Q1 24 | 0.66× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $21.3M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $21.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | 13.9% | -48.6% |
| 资本支出强度资本支出/营收 | 0.2% | 0.5% |
| 现金转化率经营现金流/净利润 | 3.52× | — |
| 过去12个月自由现金流最近4个季度 | $109.2M | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $21.3M | $-99.8M | ||
| Q3 25 | $32.5M | $-91.4M | ||
| Q2 25 | $27.0M | $-108.3M | ||
| Q1 25 | $30.7M | $-166.5M | ||
| Q4 24 | $48.4M | $-79.3M | ||
| Q3 24 | $27.5M | $-67.0M | ||
| Q2 24 | $23.9M | $-77.0M | ||
| Q1 24 | $13.3M | $-190.7M |
| Q4 25 | $21.0M | $-100.8M | ||
| Q3 25 | $31.6M | $-92.7M | ||
| Q2 25 | $26.5M | $-110.7M | ||
| Q1 25 | $30.2M | $-167.8M | ||
| Q4 24 | $48.2M | $-79.5M | ||
| Q3 24 | $27.4M | $-68.6M | ||
| Q2 24 | $23.3M | $-79.0M | ||
| Q1 24 | $12.9M | $-193.9M |
| Q4 25 | 13.9% | -48.6% | ||
| Q3 25 | 21.4% | -58.0% | ||
| Q2 25 | 17.9% | -66.5% | ||
| Q1 25 | 21.2% | -120.5% | ||
| Q4 24 | 33.5% | -48.3% | ||
| Q3 24 | 19.5% | -49.2% | ||
| Q2 24 | 16.6% | -53.7% | ||
| Q1 24 | 9.4% | -178.2% |
| Q4 25 | 0.2% | 0.5% | ||
| Q3 25 | 0.6% | 0.8% | ||
| Q2 25 | 0.3% | 1.5% | ||
| Q1 25 | 0.3% | 1.0% | ||
| Q4 24 | 0.2% | 0.1% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.5% | 1.4% | ||
| Q1 24 | 0.3% | 3.0% |
| Q4 25 | 3.52× | — | ||
| Q3 25 | 2.93× | — | ||
| Q2 25 | 3.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EVCM
| Transferred Over Time | $146.4M | 97% |
| Transferred At Point In Time | $4.8M | 3% |
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
